Germany's Merck KGaA <a href="https://www.reuters.com/markets/companies/MRCG.DE" target="_blank">(MRCG.DE)</a> said its experimental multiple sclerosis drug evobrutinib did not meet the primary goal in highly anticipated late-stage trials, dealing a major blo…